Clinical trials such as the EMPA-REG OUTCOME and CANVAS studies have highlighted the cardioprotective benefits of SGLT-2 inhibitors [18], including reductions in major adverse cardiovascular events (MACE), heart failure hospitalizations, and overall cardiovascular mortality [19]. This evidence concerns the gene SLC5A2 and heart failure.